Replies to post #1947 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV maintained its full-year 2021 Mavyret guidance of $2.0B.

[DewDiligence]

ABBV 2Q21 Mavyret sales=$441M, +6% QoQ:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2021-financial-results.htm

New-patient starts are increasing but are not (yet) back to pre-pandemic levels.

ABBV’s full-year 2021 Mavyret guidance is $1.9B, down from the prior guidance of $2.0B.